Cargando…
ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression
Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 liga...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114478/ https://www.ncbi.nlm.nih.gov/pubmed/35600879 http://dx.doi.org/10.3389/fphar.2022.858901 |
_version_ | 1784709784204738560 |
---|---|
author | Deng, Yuanfei Yu, Cuifu Chen, Lushi Zhang, Xin Lei, Qiucheng Liu, Qing Cai, Gengxi Liu, Fang |
author_facet | Deng, Yuanfei Yu, Cuifu Chen, Lushi Zhang, Xin Lei, Qiucheng Liu, Qing Cai, Gengxi Liu, Fang |
author_sort | Deng, Yuanfei |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 ligases, have become the advanced tools and attractive molecules for cancer treatment. However, the anticancer effects of PROTACs in HCC remain to be clarified. Here, we evaluate the anticancer activity of ARV-771, a previously reported PROTAC compound designed for bromodomain and extra-terminal domain (BET) proteins, in HCC. We show that ARV-771 suppresses the cell viability and colony formation of HCC cells via arresting cell cycle progression and triggering apoptosis. Further investigations reveal that ARV-771 notably downregulates multiple non-proteasomal deubiquitinases which are critical to the development of cancers. Additionally, HCC cells can decrease their sensitivity to ARV-771 via activating the MEK/ERK and p38 MAPKs. ARV-771 also inhibits HCC progression in vivo. Moreover, we show that ARV-771 and sorafenib, a Raf inhibitor that clinically used for targeted therapy of liver cancer, can synergistically inhibit the growth of HCC cells. Overall, this study not only explores the anticancer activity of ARV-771 and its underlying mechanisms in HCC, but also deepens our understanding of deubiquitinases, MAPKs, cell cycle, and apoptosis induction in cancer therapy. |
format | Online Article Text |
id | pubmed-9114478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91144782022-05-19 ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression Deng, Yuanfei Yu, Cuifu Chen, Lushi Zhang, Xin Lei, Qiucheng Liu, Qing Cai, Gengxi Liu, Fang Front Pharmacol Pharmacology Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 ligases, have become the advanced tools and attractive molecules for cancer treatment. However, the anticancer effects of PROTACs in HCC remain to be clarified. Here, we evaluate the anticancer activity of ARV-771, a previously reported PROTAC compound designed for bromodomain and extra-terminal domain (BET) proteins, in HCC. We show that ARV-771 suppresses the cell viability and colony formation of HCC cells via arresting cell cycle progression and triggering apoptosis. Further investigations reveal that ARV-771 notably downregulates multiple non-proteasomal deubiquitinases which are critical to the development of cancers. Additionally, HCC cells can decrease their sensitivity to ARV-771 via activating the MEK/ERK and p38 MAPKs. ARV-771 also inhibits HCC progression in vivo. Moreover, we show that ARV-771 and sorafenib, a Raf inhibitor that clinically used for targeted therapy of liver cancer, can synergistically inhibit the growth of HCC cells. Overall, this study not only explores the anticancer activity of ARV-771 and its underlying mechanisms in HCC, but also deepens our understanding of deubiquitinases, MAPKs, cell cycle, and apoptosis induction in cancer therapy. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9114478/ /pubmed/35600879 http://dx.doi.org/10.3389/fphar.2022.858901 Text en Copyright © 2022 Deng, Yu, Chen, Zhang, Lei, Liu, Cai and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Deng, Yuanfei Yu, Cuifu Chen, Lushi Zhang, Xin Lei, Qiucheng Liu, Qing Cai, Gengxi Liu, Fang ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title_full | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title_fullStr | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title_full_unstemmed | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title_short | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
title_sort | arv-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114478/ https://www.ncbi.nlm.nih.gov/pubmed/35600879 http://dx.doi.org/10.3389/fphar.2022.858901 |
work_keys_str_mv | AT dengyuanfei arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT yucuifu arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT chenlushi arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT zhangxin arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT leiqiucheng arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT liuqing arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT caigengxi arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT liufang arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression |